▲ 0.20%
prev close
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Congressional Trades
10
All tracked trades
Members Trading
4
Unique members
Net Activity
+2
6 buys · 4 sells
Members Who Traded This Stock
10 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-10-31 | NVONovo Nordisk A/S Common Stock | Sell | $1,001 - $15,000 | 243d ago | — | |
| 2025-10-30 | NVONovo Nordisk A/S Common Stock | Sell | $1,001 - $15,000 | 243d ago | — | |
| 2025-09-11 | NVONovo Nordisk A/S Common Stock | Buy | $1,001 - $15,000 | 273d ago | — | |
| 2025-08-04 | NVONovo Nordisk A/S Common Stock | Buy | $1,001 - $15,000 | 342d ago | — | |
| 2025-08-04 | NVONovo Nordisk A/S Common Stock | Sell | $1,001 - $15,000 | 313d ago | — | |
| 2025-08-04 | NVONovo Nordisk A/S Common Stock | Buy | $15,001 - $50,000 | 342d ago | — | |
| 2025-06-09 | NVONovo Nordisk A/S Common Stock | Buy | $1,001 - $15,000 | 343d ago | — | |
| 2025-03-27 | NVONovo Nordisk A/S Common Stock | Buy | $15,001 - $50,000 | 467d ago | — | |
| 2024-10-29 | NVONovo Nordisk A/S Common Stock | Buy | $1,001 - $15,000 | 313d ago | — | |
| 2023-07-12 | NVONovo Nordisk A/S Common Stock | Sell | $100,001 - | 1074d ago | — |
2025-10-31
Lisa McClain
NVO
Amount
$1,001 - $15,000
Filed
243d ago
2025-10-30
Lisa McClain
NVO
Amount
$1,001 - $15,000
Filed
243d ago
2025-09-11
Lisa McClain
NVO
Amount
$1,001 - $15,000
Filed
273d ago
2025-08-04
Scott Scott Franklin
NVO
Amount
$1,001 - $15,000
Filed
342d ago
2025-08-04
Lisa McClain
NVO
Amount
$1,001 - $15,000
Filed
313d ago
2025-08-04
Scott Scott Franklin
NVO
Amount
$15,001 - $50,000
Filed
342d ago
2025-06-09
Lisa McClain
NVO
Amount
$1,001 - $15,000
Filed
343d ago
2025-03-27
Scott Scott Franklin
NVO
Amount
$15,001 - $50,000
Filed
467d ago
2024-10-29
Valerie Hoyle
NVO
Amount
$1,001 - $15,000
Filed
313d ago
2023-07-12
Daniel Goldman
NVO
Amount
$100,001 -
Filed
1074d ago
Recent News
Powered by Polygon.io
New study finds GLP-1 receptor agonists associated with lower risk of alcohol-related hospitalization among adults with alcohol use disorder
"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks.
Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing
Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?
Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China
Trade Timeline
Congressional activity, newest first
Lisa McClain
2025-10-31 · Sale
$1,001 - $15,000
Lisa McClain
2025-10-30 · Sale
$1,001 - $15,000
Lisa McClain
2025-09-11 · Purchase
$1,001 - $15,000
Scott Scott Franklin
2025-08-04 · Purchase
$1,001 - $15,000
Lisa McClain
2025-08-04 · Sale
$1,001 - $15,000
Scott Scott Franklin
2025-08-04 · Purchase
$15,001 - $50,000
Lisa McClain
2025-06-09 · Purchase
$1,001 - $15,000
Scott Scott Franklin
2025-03-27 · Purchase
$15,001 - $50,000
Valerie Hoyle
2024-10-29 · Purchase
$1,001 - $15,000
Daniel Goldman
2023-07-12 · Sale
$100,001 -